Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bamberg

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Journal of Cancer Research and Clinical Oncology|April 24, 2017
Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trialUlrich Herrlinger, Niklas Schäfer, Rolf Fimmers, et al.
Wiener Klinische Wochenschrift|June 24, 2006
3-D Conformal radiotherapy of localized prostate cancer within an Austrian-German multicenter trial: a prospective study of patients' acceptance of the rectal balloon during treatmentGregor Goldner, Hans Geinitz, Stefan Wachter, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 8, 2005
3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effectsGregor Goldner, Frank Zimmermann, Horst Feldmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 26, 2009
Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trialGregor Goldner, Valentin Bombosch, Hans Geinitz, et al.
Annals of Neurology|September 27, 2002
Gliomatosis cerebri: molecular pathology and clinical courseUlrich Herrlinger, Jörg Felsberg, Wilhelm Küker, et al.
BMC Cancer|July 29, 2005
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definitionUte Ganswindt, Frank Paulsen, Stefan Corvin, et al.
Onkologie|February 5, 2005
Meeting report: primary central nervous system lymphoma: standards of care and future perspectivesUlrich Herrlinger, Agnieszka Korfel, Holger Hebart, et al.
Cancer Research|February 7, 2002
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesisCorinne L Reimer, Naoki Agata, Jennifer G Tammam, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patientsGregor Goldner, Birgit Tomicek, Gerd Becker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized TrialVolker Budach, Martin Stuschke, Wilfried Budach, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Journal of Cancer Research and Clinical Oncology|April 24, 2017
Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trialUlrich Herrlinger, Niklas Schäfer, Rolf Fimmers, et al.
Wiener Klinische Wochenschrift|June 24, 2006
3-D Conformal radiotherapy of localized prostate cancer within an Austrian-German multicenter trial: a prospective study of patients' acceptance of the rectal balloon during treatmentGregor Goldner, Hans Geinitz, Stefan Wachter, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 8, 2005
3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effectsGregor Goldner, Frank Zimmermann, Horst Feldmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 26, 2009
Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trialGregor Goldner, Valentin Bombosch, Hans Geinitz, et al.
Annals of Neurology|September 27, 2002
Gliomatosis cerebri: molecular pathology and clinical courseUlrich Herrlinger, Jörg Felsberg, Wilhelm Küker, et al.
BMC Cancer|July 29, 2005
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definitionUte Ganswindt, Frank Paulsen, Stefan Corvin, et al.
Onkologie|February 5, 2005
Meeting report: primary central nervous system lymphoma: standards of care and future perspectivesUlrich Herrlinger, Agnieszka Korfel, Holger Hebart, et al.
Cancer Research|February 7, 2002
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesisCorinne L Reimer, Naoki Agata, Jennifer G Tammam, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patientsGregor Goldner, Birgit Tomicek, Gerd Becker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized TrialVolker Budach, Martin Stuschke, Wilfried Budach, et al.
Pageof 13